[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dutcher, 2013 - Google Patents

Recent developments in the treatment of renal cell carcinoma

Dutcher, 2013

View HTML @Full View
Document ID
12419881846145073666
Author
Dutcher J
Publication year
Publication venue
Therapeutic advances in urology

External Links

Snippet

Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the …
Continue reading at journals.sagepub.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer

Similar Documents

Publication Publication Date Title
Dutcher Recent developments in the treatment of renal cell carcinoma
Isaacsson Velho et al. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Gaudreau et al. Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC
Qu et al. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Ganesh et al. Immunotherapy in colorectal cancer: rationale, challenges and potential
Osa et al. Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
Gide et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma
Ben‐Ami et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study
Chocarro de Erauso et al. Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon?
Atkins et al. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives
Weinstock et al. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
Packer et al. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference
Smith et al. Nivolumab for the treatment of colorectal cancer
Ficial et al. Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma
Le Du et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Mina et al. Immunotherapy for the treatment of breast cancer: emerging new data
Lim et al. Pembrolizumab for the treatment of non-small cell lung cancer
Khattak et al. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Ciccarese et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Lerner et al. Summary and recommendations from the National Cancer Institute’s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer
Mantia et al. Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Rihawi et al. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
Ninomiya et al. Pembrolizumab for the first-line treatment of non-small cell lung cancer
Shen et al. Highlights on immune checkpoint inhibitors in non–small cell lung cancer
Alaia et al. Ipilimumab for the treatment of metastatic prostate cancer